GlaxoSmithKline stopped a late-stage trial of its cancer vaccine after a series of disappointing results, adding to a series of drug-development woes for the U.K. pharmaceutical company.
from WSJ.com: US Business http://ift.tt/1h1GAp0
via IFTTT
from WSJ.com: US Business http://ift.tt/1h1GAp0
via IFTTT
No comments:
Post a Comment